Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.

David M. OMalley,Ursula A. Matulonis,Michael J. Birrer,Cesar M. Castro,Ignace Vergote,Lainie P. Martin,Gina Mantia-Smaldone,Lucy Gilbert,Antonio González-Martín,Raquel Bratos,Brooke Esteves,Karim Malek,Kathleen N. Moore

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.

2019

David M. OMalley
Ursula A. Matulonis
Michael J. Birrer
Cesar M. Castro
Ignace Vergote
Lainie P. Martin
Gina Mantia-Smaldone
Lucy Gilbert
Antonio González-Martín
Raquel Bratos
Brooke Esteves
Karim Malek
Kathleen N. Moore

5520Background: Mirvetuximab soravtansine is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. As part of the Phase 1b FORWARD ...

Keywords:

MIRVETUXIMAB SORAVTANSINE
Bevacizumab
in patient
Medicine
Folate Receptor Alpha
Antibody-drug conjugate
Ovarian cancer
Cancer research
Antibody
platinum resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations